NBIX
Neurocrine Biosciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$155.64
−1.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.4B | 2.9B | 2.4B | 1.9B | 1.5B |
| Cost of Revenue | 68.6M | 52.1M | 34.0M | 39.7M | 23.2M |
| Gross Profit | 3.3B | 2.8B | 2.3B | 1.8B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 1.1B | 1.0B | 731.1M | 565.0M | 463.8M |
| SG&A Expense | 1.4B | 1.2B | 1.0B | 887.6M | 752.7M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 33.7M | 17.4M | 12.5M | 143.9M | — |
| Total Operating Expenses | 2.5B | 2.2B | 1.8B | 1.6B | 1.2B |
| Cost and Expenses | 2.6B | 2.2B | 1.8B | 1.6B | 1.2B |
| Operating Income (EBIT) | 788.9M | 619.1M | 570.5M | 250.9M | 249.0M |
| Non-Operating | |||||
| Interest Income | 7.5M | 90.3M | 91.0M | — | 11.2M |
| Interest Expense | 2.9M | — | 126.6M | 4.6M | 7.1M |
| Net Interest Income | 4.6M | 90.3M | (35.6M) | (4.6M) | 4.1M |
| Other Non-Op Income/Expense | 151.3M | 86.3M | (84.5M) | 81.2M | (35.1M) |
| Non-Operating Income (excl Interest) | (81.9M) | (17.4M) | (42.1M) | (143.9M) | 28.0M |
| EBT (Pre-Tax Income) | 940.2M | 705.4M | 486.0M | 332.1M | 213.9M |
| Income Tax Expense | 234.7M | 226.8M | 144.7M | 82.4M | 59.4M |
| Bottom Line | |||||
| Net Income | 705.5M | 478.6M | 341.3M | 249.7M | 154.5M |
| Earnings from Cont. Ops | 705.5M | 478.6M | 341.3M | 249.7M | 154.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 705.5M | 478.6M | 341.3M | 249.7M | 154.5M |
| Per Share | |||||
| Basic EPS | $7.05 | $4.81 | $3.40 | $2.56 | $1.61 |
| Diluted EPS | $6.82 | $4.67 | $3.29 | $2.47 | $1.56 |
| Revenue Per Share | $33.40 | $28.75 | $23.46 | $19.32 | $15.54 |
| Shares | |||||
| Basic Shares Outstanding | 101.0M | 99.5M | 100.4M | 97.7M | 95.8M |
| Diluted Shares Outstanding | 104.2M | 102.5M | 103.7M | 101.0M | 98.9M |
| Profitability Metrics | |||||
| EBITDA | 918.1M | 666.6M | 639.7M | 416.1M | 236.6M |
| D&A | 47.3M | 30.1M | 27.1M | 21.3M | 15.6M |
| EBIT | 870.8M | 636.5M | 612.6M | 394.8M | 221.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026